FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukemia with a NPM1 Mutation

The FDA approved ziftomenib, a menin inhibitor, for adults with relapsed or refractory AML with a susceptible nucleophosmin 1 mutation who have no satisfactory alternative treatment options.